HLA Downregulation in Allogeneic Cell Therapies to Enhance Persistence Using an Integrated shRNA-targeting ApproachThis novel genetic construct for allogeneic cellular therapies enables immune‑evasive persistence by selectively downregulating HLA class I molecules while preserving natural killer (NK) cell inhibition. |
Tech ID2025-029 College(None) Licensing ManagerInventorsCategories(None) |
